Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
Why ?
Steadyman - save this as a a bookmark.
https://www.londonstockexchange.com/stock/AVCT/avacta-group-plc/analysis
In case the late comers missed this
https://www.businesswire.com/news/home/20210106005853/en/Adeptrix-Closes-Series-A-Financing-to-Commercialize-BAMS
Avacta Group plc
("Avacta", the "Company" or the "Group")
License Agreement with POINT Biopharma Inc.
License to utilise Avacta's pre|CISIONTM FAP sensitive activation platform for radiopharmaceuticals
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc. ("POINT"), to provide access to Avacta's pre|CISION™ technology for the development of tumour-activated radiopharmaceuticals.
The radiopharmaceutical market is expected to grow to $15 billion by 20251 and there is a substantial opportunity to grow much faster if safety and tolerability of these effective treatments can be improved. POINT Biopharma is a clinical-stage pharmaceutical company focused on developing radioligands2 as precision medicines for the treatment of cancer.
Avacta's proprietary pre|CISIONTM chemistry can be used to modify a radioligand drug to form a tumour-activated prodrug. The prodrug form is inactive in circulation until it enters the tumour micro-environment where it is activated by an enzyme called fibroblast activation protein (or FAP) that is present in high abundance in most solid tumours but not in healthy tissue. Avacta's pre|CISION™ technology therefore has the potential to improve the tolerability and achieve better clinical outcomes for patients compared with standard radiopharmaceuticals by targeting the radioligand treatment more specifically to cancer cells.
The agreement provides POINT with an exclusive license to the pre|CISION technology for use in the first radiopharmaceutical prodrug the company intends to develop, and a non-exclusive license to the pre|CISION™ platform for the development of a broader pipeline of FAP-activated radiopharmaceuticals.
Under the terms of the agreement, Avacta will receive an upfront fee and development milestones for the first radiopharmaceutical prodrug totalling $9.5 million. Avacta will also receive milestone payments for subsequent radiopharmaceutical prodrugs of up to $8 million each, a royalty on sales of FAP-activated radiopharmaceuticals by POINT and a percentage of any sublicensing income received by POINT.
Alastair Smith, Chief Executive Officer of Avacta Group, commented:
"I am very pleased to have established this partnership with POINT that allows Avacta to exploit its pre|CISION platform in a therapeutic area outside of our in-house focus on chemotherapy prodrugs.
The clinical and commercial rationale for our pre|CISION prodrug platform is to improve the safety and efficacy of many existing drugs, as well as generating a pipeline of new and novel cancer therapies. In oncology, we believe that this approach will result in better response rates for monotherapies, and a greater safety margin, to enable their use with a larger patient population and as part of combination therapies.
I should have added the headliner.....
Adeptrix Closes Series A Financing to Commercialize BAMS™ Bioanalytical Reagents for Life Science Research
Thanks Arnold
Wonder who they are making these for ?
https://bidstats.uk/tenders/2021/W01/742392033
https://www.adrecoplastics.co.uk/medical-injection-moulding/
https://bidstats.uk/tenders/?q=covid-19&ntype=award&value=high#742326271-742260932-19
https://www.lse.co.uk/rns/AVCT/result-of-fundraising-b1h498y4lkcjkxx.html
Actually ....the April RNS was for £5 million and the later larger fund raise RNS was in June.... so it might still be due .
Muck165 - my thinking was that all of the projects were running due to the large fund raise. But at least its good to know lots happening in the background
Thanks Muck165
Should have added link
https://avacta.com/avacta-and-selexis-partner-to-develop-cell-line-for-clinical-manufacturing/
20 Jun 2019
Avacta and Selexis partner to develop cell line for clinical manufacturing
Avacta’s first Affimer clinical candidate is a potent PD-L1 antagonist under development for solid tumour indications as the basis of bispecific and combination therapies
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, and Selexis, a pioneering life sciences company and global leader in mammalian cell line generation technology, have partnered to develop the Chinese hamster ovary (CHO) cell line that will be used to manufacture Avacta’s first Affimer clinical candidate for first-time-in-human clinical trials. This major milestone means that Avacta remains on track to submit an IND/CTA application for an Affimer PD-L1 inhibitor by the end of 2020.
Avacta’s first clinical candidate will be against PD-L1, a clinically validated immune checkpoint that plays an important role in the tumour escape mechanism in cancer. The lead molecule (AVA004) is a potent PD-L1 antagonist that has been engineered with an Fc domain for half-life extension. Avacta has demonstrated the preclinical efficacy of AVA004 in syngeneic and xenograft mouse models and it compares favourably to approved monoclonal antibodies such as Imfinzi®, Tecentriq® and Bavencio® at the doses administered.
Alastair Smith, Avacta Group Chief Executive Officer, commented:
“The strategic partnership with Selexis allows Avacta to access the technology and know-how to develop high-expressing CHO cell lines as well as the extensive experience of developing a range of Fc fusion proteins for clinical manufacturing. These cell lines are the essential basis of clinical manufacturing of AVA004 and this partnership supports Avacta’s strategy to demonstrate safety and tolerability of the Affimer platform in humans with a planned IND/CTA by the end of 2020.
The ultimate aim is to combine AVA004 with other Affimer checkpoint modulators in bispecific cancer immunotherapies, and with novel chemotherapies as drug conjugates and combination therapies utilising proprietary tumour microenvironment targeting chemistry. These approaches seek to combine modulation of the adaptive immune response with stimulation of the innate immune system, with the aim of improving the clinical outcome for the sizeable proportion of solid tumour patients having “cold” tumours that do not respond to checkpoint inhibitors alone.”
Marco Bocci, PhD, Dpharm, Selexis Senior Vice President, Licensing and Business Development commented:
“Our agreement with Avacta is a result of Selexis’ leadership in bringing an innovative technology solution to our partners and the capability to enhance speed in drug development, including for those developing therapeutics that are beyond traditional monoclonal antibodies. It is rewarding for us to play a role as Avacta prepares to advance its first Affimer clinical candidate into the clinic.”
Home test results....
https://www.chroniclelive.co.uk/news/north-east-news/coronavirus-test-waiting-times-surge-19544137
Still waiting on mass spectrometry...
https://bidstats.uk/tenders/2020/W47/739311716